Skip to main content

Table 3 Multivariate Cox analysis of clinical variables and marker groups in tamoxifen-treated (cohort 1) and untreated patients

From: Proliferation and estrogen signaling can distinguish patients at risk for early versus late relapse among estrogen receptor positive breast cancers

  Tamoxifen-treated patients (cohort 1) Untreated patients
  0.0 to 2.5 yearsa 5.0 to 10.0 yearsa,c 0.0 to 2.5 yearsb 5.0 to 10.0 yearsb,c
Variable Hazard ratio (95% CI) P Hazard ratio (95% CI) P Hazard ratio(95% CI) P Hazard ratio(95% CI) P
Age, analyzed as a continuous variable 1.04 (0.99, 1.08) 0.071 1.02 (0.98, 1.07) 0.279 1.01 (0.98, 1.05) 0.357 1.04 (0.99, 1.08) 0.063
Tumor (T) stage, T2/3 vs T1 2.29 (0.87, 6.08) 0.094 2.90 (1.22, 6.91) 0.016 1.88 (0.74, 4.80) 0.183 1.22 (0.48, 3.12) 0.677
Nodal status, positive vs negative 2.92 (1.23, 6.88) 0.014 2.46 (1.15, 5.23) 0.021 - -   
Grade 2 or 3 vs 1 1.51 (0.33, 6.78) 0.592 0.72 (0.31, 1.69) 0.451 2.13 (0.28, 16.4) 0.467 1.07 (0.29, 3.95) 0.923
HER2-positive vs -negative 1.42 (0.33, 6.78) 0.528 1.63 (0.31, 1.69) 0.667 4.24 (1.36, 13.1) 0.013 2.89 (0.57, 14.6) 0.198
MKS/ERS (ref lowMKS/highERS)         
   lowMKS/lowERS 2.65 (0.48, 14.7) 0.269 3.53 (1.21, 10.2) 0.021 1.67 (0.10, 27.1) 0.717 0.46 (0.09, 2.33) 0.349
   highMKS/highERS 1.28 (0.18, 9.23) 0.807 4.59 (1.56, 13.5) 0.006 11.6 (1.41, 95.2) 0.023 1.82 (0.53, 6.27) 0.343
   highMKS/lowERS 10.0 (2.21, 45.5) 0.003 0.95 (0.20, 4.70) 0.947 9.56 (1.17, 77.8) 0.035 1.51 (0.44, 5.14) 0.508
  1. Note: only patients with all data available were considered in multivariate analysis. aTime interval 0.0 to 2.5 years: 434 patients (29 events); time interval 5.0 to 10.0 years: 323 patients (34 events). bTime interval 0.0 to 2.5 years: 320 patients (20 events); time interval 5.0 to 10.0 years: 256 patients (19 events). Cox multivariate analysis was performed also excluding tumor stage (which accounted for the majority of the missing data) with similar results (458 patients (40 events) and 349 patients (28 events) in 0.0 to 2.5 and 5.0 to 10 years, respectively). cP = 0.0002 (tamoxifen, 0.0 to 2.5 years), P = 0.003 (tamoxifen, 5.0 to 10.0 years), P = 0.006 (untreated, 0.0 to 2.5 years), P = 0.361 (untreated, 5.0 to 10.0 years) for the comparison of the multivariate models with and without the MKS/ERS groups (by the likelihood-ratio test). MKS, mitotic kinase score; ERS, estrogen-related score. P-values in boldface were statistically significant at P <0.05.